HYAL2

Across TCGA pan-cancer cohorts, HYAL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HYAL2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher HYAL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HYAL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LSCC, LUAD, and UCEC are the cancer types where HYAL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.632	0.911	.001	20	view →
LUAD	DFS	Median	II,III,IV	0.790	0.869	.025	15	view →
UCEC	OS	Tertile	All	1.000	0.802	.026	6	view →
PDAC	DFS	Median	III,IV	0.977	0.495	.020	4	view →
HNSC	DFS	Median	IV	0.866	0.512	.009	4	view →
CCRCC	OS	Median	III,IV	0.848	0.559	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HYAL2–LSCC (OS)

Open the LSCC breakdown →